New Delhi, Mar 13 (UNI) Drug maker Cadila Healthcare Ltd, part of the Zydus Cadila group, today said it had received tentative approval from the US Food and Drug Administration (USFDA) to market its cardiovascular drug Carvedilol tablets.
The drug is used to treat heart failure and high blood pressure.
The current sale of Carvedilol tablets in the US market as per NDC Health is estimated at 1.24 billion dollars, Cadila said in a statement.
The group had recently received the tentative approval to market Sertraline Hydrochloride Tablets, 25 mg, 50 mg and 100 mg, in the US market.
UNI SR SD PM1637